XTL Biopharmaceuticals Ltd (XTLB) — Working Capital to Net Assets Ratio
XTL Biopharmaceuticals Ltd (XTLB) has a Working Capital to Net Assets ratio of -16.0% as of December 2024. Working capital of ILA-867.00K (current assets of ILA1.34 Million minus current liabilities of ILA2.21 Million) is measured against net assets of ILA5.43 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See XTL Biopharmaceuticals Ltd (XTLB) balance sheet quality index to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
XTL Biopharmaceuticals Ltd Working Capital to Net Assets (2013–2024)
This chart shows how XTL Biopharmaceuticals Ltd's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2013 to 2024. As of December 2024, the ratio stands at -16.0%, reflecting working capital of ILA-867.00K against net assets of ILA5.43 Million ILA. Check how tangible is XTL Biopharmaceuticals Ltd's equity to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for XTL Biopharmaceuticals Ltd (2013–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for XTL Biopharmaceuticals Ltd from 2013 to 2024, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see XTL Biopharmaceuticals Ltd market capitalisation.
| Year | WC/NA Ratio | Working Capital (ILA) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -16.0% | ILA-867.00K | ILA5.43 Million | ILA1.34 Million | ILA2.21 Million | ▼ -98.8 pp |
| 2023 | 82.9% | ILA1.84 Million | ILA2.22 Million | ILA2.05 Million | ILA206.00K | ▼ -7.6 pp |
| 2022 | 90.5% | ILA3.62 Million | ILA4.00 Million | ILA3.81 Million | ILA187.00K | ▼ -22.1 pp |
| 2021 | 112.6% | ILA6.01 Million | ILA5.33 Million | ILA6.24 Million | ILA231.00K | ▲ +18.7 pp |
| 2020 | 93.9% | ILA5.87 Million | ILA6.25 Million | ILA6.12 Million | ILA254.00K | ▼ -0.6 pp |
| 2019 | 94.5% | ILA6.60 Million | ILA6.98 Million | ILA6.83 Million | ILA232.00K | ▼ -0.9 pp |
| 2018 | 95.4% | ILA7.94 Million | ILA8.32 Million | ILA8.20 Million | ILA253.00K | ▼ -67.8 pp |
| 2017 | 163.2% | ILA5.91 Million | ILA3.62 Million | ILA6.21 Million | ILA300.00K | ▲ +73.0 pp |
| 2016 | 90.2% | ILA2.42 Million | ILA2.69 Million | ILA2.75 Million | ILA330.00K | ▲ +11.9 pp |
| 2015 | 78.4% | ILA3.83 Million | ILA4.89 Million | ILA4.26 Million | ILA436.00K | ▲ +32.7 pp |
| 2014 | 45.7% | ILA2.14 Million | ILA4.68 Million | ILA3.10 Million | ILA965.00K | ▼ -11.4 pp |
| 2013 | 57.0% | ILA3.87 Million | ILA6.79 Million | ILA5.09 Million | ILA1.22 Million | — |